These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22940072)

  • 21. Pharmacology of imatinib (STI571).
    Buchdunger E; O'Reilly T; Wood J
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S28-36. PubMed ID: 12528770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
    O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
    J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficiency and Toxicity of Imatinib Mesylate Combined with Atorvastatin Calcium in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease: A Single-Center, Prospective, Single-Arm, Open-Label Study.
    Chen T; Li J; Wei X; Yao H; Zhu L; Liu J; Liu Y; Wang P; Feng Y; Gao S; Liu H; Wang L; Zhao L; Gao L; Zhang C; Gao L; Zhang X; Kong P
    Acta Haematol; 2024; 147(5):499-510. PubMed ID: 38232716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
    J Invest Dermatol; 2012 Dec; 132(12):2752-61. PubMed ID: 22810302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D; Kimura H; Date M; Hamaguchi Y; Hasegawa M; Hau KT; Fujimoto M; Takehara K; Matsushita T
    J Dermatol Sci; 2014 Jun; 74(3):214-21. PubMed ID: 24679982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Tedder TF; Fujimoto M
    Blood; 2013 Apr; 121(16):3274-83. PubMed ID: 23422748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
    van Steensel L; Paridaens D; Schrijver B; Dingjan GM; van Daele PL; van Hagen PM; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful long-term use of imatinib mesylate in pediatric patients with sclerodermatous chronic GVHD.
    Kim H; Kim NH; Kang HJ; Lee JW; Kim MS; Park KD; Shin HY; Ahn HS
    Pediatr Transplant; 2012 Dec; 16(8):910-2. PubMed ID: 23050745
    [No Abstract]   [Full Text] [Related]  

  • 29. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
    Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB
    Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
    Ammoun S; Schmid MC; Triner J; Manley P; Hanemann CO
    Neuro Oncol; 2011 Jul; 13(7):759-66. PubMed ID: 21727212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
    Abouantoun TJ; MacDonald TJ
    Mol Cancer Ther; 2009 May; 8(5):1137-47. PubMed ID: 19417143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.
    Pierobon M; Silvestri A; Spira A; Reeder A; Pin E; Banks S; Parasido E; Edmiston K; Liotta L; Petricoin E
    J Proteome Res; 2014 Jun; 13(6):2846-55. PubMed ID: 24787230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer.
    Shinagawa K; Kitadai Y; Tanaka M; Sumida T; Onoyama M; Ohnishi M; Ohara E; Higashi Y; Tanaka S; Yasui W; Chayama K
    Int J Cancer; 2013 Feb; 132(4):813-23. PubMed ID: 22821812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).
    Srour M; Alsuliman T; Labreuche J; Bulabois CE; Chevallier P; Daguindau E; Forcade E; François S; Guillerm G; Coiteux V; Turlure P; Beguin Y; Yakoub-Agha I; Magro L
    Bone Marrow Transplant; 2023 Apr; 58(4):401-406. PubMed ID: 36624161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice.
    Rhee CK; Lee SH; Yoon HK; Kim SC; Lee SY; Kwon SS; Kim YK; Kim KH; Kim TJ; Kim JW
    Respiration; 2011; 82(3):273-87. PubMed ID: 21659722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors.
    Chu S; Alexiadis M; Fuller PJ
    Gynecol Oncol; 2008 Jan; 108(1):182-90. PubMed ID: 18028988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
    Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
    Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo.
    Wang S; Wilkes MC; Leof EB; Hirschberg R
    FASEB J; 2005 Jan; 19(1):1-11. PubMed ID: 15629889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling.
    Chen CW; Beyer C; Liu J; Maier C; Li C; Trinh-Minh T; Xu X; Cole SH; Hsieh MH; Ng N; Althage A; Meeusen S; Pan S; Svensson EC; Seidel HM; Schett G; Gergely P; Harris JL; Distler JH
    Ann Rheum Dis; 2017 Apr; 76(4):773-778. PubMed ID: 28153829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.